18F-FDG-PET/CT in potentially advanced renal cell carcinoma: A role in treatment decisions and prognosis estimation

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2665-2672

  Ferda, Jiri ^a   Ferdova, Eva ^a   Hora, Milan ^a   Hes, Ondrej ^a   Finek, Jindrich ^a   Topolcan, Ondrej ^a   Kreuzberg, Boris ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

18F FDG PET CT; Hybrid imaging; Prognosis; Renal cell carcinoma; SUVmax

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOMEPROL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG ACCUMULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR BIOPSY; 18F-FDG-PET/CT; ANGIOGRAPHY; HYBRID IMAGING; KIDNEY; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SCINTISCANNING; SURVIVAL; SUVMAX; VERY ELDERLY;

18F-FDG-PET/CT; HYBRID IMAGING; PROGNOSIS; RENAL CELL CARCINOMA; SUVMAX;

AGED; AGED, 80 AND OVER; ANGIOGRAPHY; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 84881325657     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Motzer RJ, Bander NH and Nanus DM: Renal cell carcinoma N Engl J Med 335: 865-875, 1996.
2. Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, Coppenrath E, Degenhart C, Graser A, Scherr M and Reiser MF: Staging of renal cell carcinoma. Eur Radiol 17(9): 2268-2277, 2007.
3. Ferda J, Hora M, Hes O, Ferdová E and Kreuzberg B: Assessment of the kidney tumor vascular supply by two-phase MDCT-Angiography. Eur J Radiol 62(2): 295-301, 2007.
4. Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, Sobrio F, Bouvard G and Agostini D: Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol. Imaging 30(9): 1236-1245, 2003.
5. Lawrentschuk N, Davis ID, Bolton DM and Scott AM. Functional imaging of renal cell carcinoma. Nat Rev Urol 7(5): 258-266, 2010.
6. Harrison MR and George DJ: Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. Clin Cancer Res 17(18): 5841-5843, 2011.
7. Ide M, Suzuki Y, Kameyama G, Takahashi W, Koide S, Hinohara S, Kawada S: The detection of renal cell carcinoma with adrenal and para-Aortic lymph node metastases by FDG-PET. Eur J Nucl Med Mol Imaging 32(10): 1246, 2005.
8. Nakatani K, Nakamoto Y, Saga T, Higashi T and Togashi K: The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol 79(1): 29-35, 2011.
9. Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y and Nakaigawa N: Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: A preliminary report. BMC Cancer 10: 667, 2010
10. Lyrdal D, Boijsen M, Suurküla M, Lundstam S and Stierner U: Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30(7): 519-524, 2009.
11. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, Itti E, Cuenod CA, Chatellier G, Oudard S and Faraggi M: Hypoxia in Renal Cancer Multicenter Group. Metastatic renal cell carcinoma: Relationship between initial metastasis hypoxia, change after one month's sunitinib, and therapeutic response: An 18F-fluoromisonidazole PET/CT study. J Nucl Med 52(7): 1048-1055, 2011.
12. Khandani AH, Cowey CL, Moore DT, Gohil H and Rathmell WK. Primary renal cell carcinoma: relationship between 18FFDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun 33(9): 967-973, 2012.
13. Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N: Early Assessment by FDG-PET/CT of Patients with Advanced Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors is Predictive of Disease Course. BMC Cancer 12(1): 162, 2012.
14. Kotzerke J, Linné C Meinhardt M, Steinbach J, Wirth M, Baretton G, Abolmaali N and Beuthien-Baumann B: [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 34(6): 884-888, 2007.
15. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, Fujibayashi Y, Yonekura Y, Welch MJ and Yokoyama O: 11CAcetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 36(3): 422-127, 2009.
16. Middendorp M, Maute L, Sauter B, Vogl TJ and Grünwald F: Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 24(6): 441-446, 2010.
17. Lawrentschuk N, Poon AM and Scott AM: Fluorine-18 fluorothymidine: A new positron emission radioisotope for renal tumors. Clin Nucl Med 31(12): 788-789, 2006.
18. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, Bolton DM and Scott AM: Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96(4): 540-546, 2005.
19. Lawrentschuk N, Gani J, Riordan R, Esler Sand Bolton DM: Multidetector computed tomography vs. magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: A study and review. BJU Int 96(3): 291-295, 2005.